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ABSTRACT

Cell-based sensing of endocrine disrupting substances using fluorescent
protein-gold nanoparticle complexes
May 2014
XIAN WANG, B.S., NANJING UNIVERSITY
M.Sc., NEW MEXICO STATE UNIVERSITY
M.Sc., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Vincent M. Rotello

Developing a sensitive and effective in vitro bioassay to detect endocrine disrupting
chemicals (EDCs) would reduce the cost, eliminate the possibility of low dose effects,
detect the non-monotonic dose responses, and identify mechanisms of actions. The
“chemical nose” sensing method using supramolecular complexes composed of cationic
monolayer functionalized gold nanoparticles (AuNPs) and fluorescent proteins (FPs) can
successfully distinguish serum proteins, mammalian cells, tissue lysates, and
chemotherapeutic drug mechanisms. EDCs regulate target cells via genomic or nongenomic pathways in terms of proliferative effect and response time. In this thesis, green
fluorescent protein-gold nanoparticle (GFP-AuNP) sensors were used to detect the
proliferative effect of 17-estradiol (E2) and bisphenol A (BPA) on MCF7 and T47D cell
lines at fM or pM dose range. Non-monotonic dose responses were also observed at
different exposure times. The dose-response relationships using GFP-AuNP sensors could
be correlated to the cell cycle analysis. Interestingly, tamoxifen, an estrogen antagonist,
showed distinct patterns at low doses on HepG2 cells using triple channel FP-AuNP
sensors, which might indicate different mechanisms of actions in this dose range.
iv
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CHAPTER 1
CELL RESPONSE SENSING AT LOW DOSES USING MULTICHANNEL
FLUORESCENT PROTEIN-GOLD NANOPARTICLE SENSORS
1.1

Introduction

1.1.1

Gold nanoparticles for biosystem sensing
Gold nanoparticles (AuNPs) provide promising sensing platforms for the detection

and quantification of nucleic acids, proteins, cells and other biosystems, hence playing a
crucial role in disease diagnosis.1,2,3 Generally, there are two functional components in
sensors, a recognition element providing selective binding sites and a transducer generating
signals upon binding events. These two components can be linked together through
covalent bonds or in the form of self-assembled supermolecular complexes. The types of
signals, mainly related to the physical properties of AuNPs, can be visible color change,
fluorescence signal release, and electrochemical signal enhancement (Figure 1.1).4,5 The
efficiency of sensors mainly relies on the recognition and transduction processes in terms
of response time, signal-to-noise ratio, selectivity, and sensitivity.7

Figure 1.1 Schematic of the AuNP-based detection system. (Ref. 6)

1

As an example, the aggregation of AuNPs (d > 3.5 nm) inducing surface plasmon
coupling can cause the visible color to change from red to blue at nanomolar
concentrations.8 Fabrication of AuNPs modified by thiolated DNA allows the
oligonucleotide-directed AuNP aggregation for colorimetric sensing of target
complementary oligonucleotides.9 In this method, two ssDNA modified AuNPs were
applied and both ends of target oligonucleotides were complementary to the base sequences
on those two modified AuNPs. The visible color change occurred in the presence of target
oligonucleotides upon DNA hybridization (Figure 1.2).

Figure 1.2 The aggregation of oligonucleotide-functionalized AuNPs (A), in the
presence of complementary target DNA, resulting in a change of solution color from red
to blue (B), can be monitored by UV-Vis spectroscopy (C). (Ref. 10)

The physical properties of monolayer-protected AuNPs, such as surface
functionalization, conductivity and plasmon resonance absorption, can be tuned by
changing the size, shape and organic or biological ligands. As a consequence, a large
variety of functionalized AuNPs of different sizes with different recognition appendages
and polyvalent abilities can be achieved.11

2

In this thesis, we focused on the physical property of AuNPs that is the fluorescence
quenching via Förster resonance energy transfer (FRET) for biosensing. The analytes in
the solution are subjected to replace some or all of the fluorophores through the recognition
sites of AuNPs to generate fluorescent signals. This is the general principle of indicator
displacement assays (IDAs) (Figure 1.3).12

Figure 1.3 Schematic representation of the molecularly imprinted polymer (MIP) sensor
array that uses a dye-displacement strategy to give a unique colorimetric response
pattern for each analyte. (Ref. 12)

1.1.2

Interaction of gold nanoparticles with proteins
The design and construction of monolayer-protected AuNPs is the key to the

success of biosensing. We designed thiol ligands covering 2-nm-core AuNPs that are
composed of three parts: a hydrophobic shell interior for the micellelike stabilization, a
tetraethyleneglycol (TEG) segment for biocompatibility and the recognition elements on
the exterior. (Figure 1.4) The TEG segment isolates the charged exterior headgroup layer
3

from the hydrophobic ligand shell interior and therefore provides the minimal requirement
of limiting the protein denaturation upon binding.13

Figure 1.4 A general scheme of surface ligands on most of the common cationic AuNPs
used for interaction with biological systems.

The thermodynamic studies of amino acid-terminated AuNP-protein interactions
reveal its similarity to protein-protein interactions in terms of entropy and enthalpy changes
(Figure 1.5).14 Appropriately modified charged AuNPs can behave as protein mimics that
bind proteins reversibly. For example, AuNPs were applied to bind cytochrome c (cyt c)
and disrupt the protein-protein interaction between cyt c and cyt c peroxidase.15

Figure 1.5 The overlap of compensation plots for protein-protein and NP-protein
interactions. (Ref. 14)

4

However, there are still differences between the AuNP-protein interaction and the
protein-protein interaction: the monolayer-protected AuNPs offer multivalent binding sites,
whereas the protein-protein interaction can be more specific like the lock and key.
Overall, tunable AuNPs provide an excellent scaffold for the recognition of target
biomolecules with high affinity, which is ideal for biosensing applications.

1.1.3

Array-based methods for protein, mammalian cell and tissue sensing
Based on the principle of IDAs, “chemical nose” sensor arrays, similar to series of

semi-selective receptors in our olfactory systems to differentiate odors, can provide
distinguishable fingerprint patterns through a composite of unbiased signals. A primary
advantage of the array-based “chemical nose” sensing strategy is to rapidly identify subtle
changes in sophisticated mixtures by effectively utilizing multivariate data analysis and
cluster analysis. Combining a set of six AuNPs with poly(phenylene ethynylene) (PPE)
polymers resulted in a distinct pattern for seven different analyte proteins.2 Using linear
discriminant analysis (LDA), seven different proteins at concentrations of 4 - 215 nM were
identified. Remarkably, the green fluorescent protein (GFP)-AuNP complexes were able
to identify five different serum proteins spiked in the undiluted human serum at a
concentration of 500 nM, where the human serum albumin (HSA) concentration only
changed 0.06%.16 In addition, as little as 200 ng of cell or tissue lysed proteins were
sufficient to distinguish disease states.17 Sensing bacteria and mammalian cells covered
with a complex mixture of biomolecules on their surfaces was also successfully achieved
by our array-based sensing strategy (Figure 1.6).3,18,19,20

5

Figure 1.6 (a) Schematic illustration of “chemical nose” sensing strategy using GFPAuNP complexes; (b) Structures of AuNPs used for sensing; (c) Differentiation of
mammalian cells by a canonical plot of discriminant analysis. (Ref. 3)

1.1.4

LDA: an essential tool to distinguish the fingerprint patterns and classify the

particular cases into tested groups
Linear discriminant analysis (LDA) is a multivariate data analysis method that is
closely related to principal component analysis (PCA) and factor analysis. It is used to
separate two or more groups of objects by performing linear combinations of independent

6

features or measurements (variables), such as fluorescent signals. In contrast, PCA is an
unsupervised method that does not include label information of data nor take into account
of any differences in groups, and factor analysis is normally used to classify variables. The
form of the discriminant function is
D = v1 X1 + v2 X2 + v3 X3 + ⋯ ⋯ + vi Xi + a
where D is the discriminant function, v is the discriminant coefficient, X is the respondent’s
score for that variable, a is a constant, and i is the number of variables. The number of
discriminant functions is one less than the number of groups. The separation is defined as
the ratio of the variance between groups to the variance within the groups.
One major aim of applying LDA is to predict to which group a particular case
belongs. In general, the case is classified as belonging to the group for which it has the
smallest Mahalanobis distance.21 The Mahalanobis distance is a measure of distance
between two points that represents the means of the group and the respective case for all
variables in the multivariate space. One way to avoid the resulting inherent bias in the
classification methodology is to use a jackknifed (or leaving-one-out) method.21 The
procedure is to determine the group classification functions when one variable is omitted
and only the remaining variables are used to calculate coefficients and constants.
Sometimes jackknifed classifications of each variable to each group are more reliable
because they do not include that variable being classified when the classification score is
calculated. Moreover, LDA can also be used to determine which variable discriminates
between groups by comparing the absolute values of standardized coefficients.

7

1.1.5

High throughput screening and chemotherapeutic drugs profiling using
unbiased multichannel sensors
In drug discovery and the fields relevant to biology and chemistry, vast libraries of

compounds were tested for activities against specific targets by means of high throughput
screening (HTS). With manually operated workstations or fully automated robotic systems,
HTS allows the testing of thousands of or millions of compounds per day. With this method
one can rapidly identify active compounds, catalytic activities from purified enzymes22,
antibodies23, phenotypic changes in intact cells24 and genes that modulate a particular
biomolecular pathway25. The HTS is viewed as the initial step of drug design and
understanding the role of a particular biochemical process in biology. The secondary
screens or follow-up assays are designed to use orthogonal methodology or biological
readout to remove hits from initial HTS that are false positives. There are several
parameters that define the format of the HTS: the nature of the signal change, the
conditional stimulus, and the response time upon stimulus.26 Using HTS assays in sequence
can lower the possibilities of false positives in substantial secondary low throughput assays
that often pertain to physiological measurements of the biological system under study.
In general, the targets of HTS involve enzymes and receptors. The major types of
protein families for specific drug targets in HTS are G protein-coupled receptors27
(GPCRs), kinases28, proteases22, nuclear receptors29 (NRs) and ion channels30. The
complexity of components and their interactions within cellular networks offering a rich
source of new therapeutic targets are also assayable by HTS. For example, the specific
kinase intracellular activity has been tested by phosphorylation-activated FRET sensors
engineered from fluorescent protein pairs.28

8

Alternative to the conventional fluorescent indicators used in HTS testing specific
targets or cellular pathways, FP-AuNP complexes can provide more general recognition
sites but specific stimulus response patterns. One significant improvement of previous
array-based chemical nose assays is to introduce multichannel FP-AuNP sensors. Its
advantages are facilitating the sensing procedure, providing simultaneous fluorescent
signals on the same samples and therefore eliminating the bias in the procedure of LDA.
More

recently,

the

molecular

mechanisms

of

apoptotic

or

necrotic

chemotherapeutic drugs have been successfully classified by applying triple-channel FPAuNP sensors onto BT549 cells (human breast cancer cell line) under the drug treatments
(Figure 1.7).31 The results imply that the phenotypic changes of cells, an adaptation in

Figure 1.7 (a) Schematic illustration of the sensing procedure; (b) LDA plot of the raw
fluorescence data from BT549 cells under the treatment of drugs; (c) The list of
chemotherapeutic drugs classified by molecular mechanisms. (Ref. 31)
9

protein expression and distribution within cellular network, can be monitored by the
unbiased sensing strategy.

1.1.6

Toxicology and dose-response relationship
Toxicology is the study of the adverse effects of chemicals or physical agents on

human and other living organisms. The adverse effects may result in immediate death or
subtle changes that are not realized until months or years later. Toxic substances or agents
can affect the entire body or specific organs. There are several factors that determine
adverse effects of toxic substances: intrinsic toxicity, dose, exposure conditions and host
response.32 Intrinsic toxicity includes the chemical and physical properties of toxic agents.
The dose of a chemical or physical agent is its amount that contacts with a living organism
at one time. In the words of Paracelsus (1493-1541), “All substances are poisons; there is
none which is not a poison. The right dose differentiates a poison from a remedy.” Studying
dose-response relationship is fundamental and essential in toxicology. In this relationship,
there is almost always a dose, known as the threshold dose, below which no response
occurs, and once the maximum response is reached, no more increased effects will happen
even with further increases in dosage. In toxicity studies, thresholds are the critical points
up to which cells can still repair damage and detoxify the exposed chemicals. The threshold
dose is normally used for determining a no observable adverse effect level (NOAEL),
which is essential for assigning the safety levels. The dose-response curve is normally
sigmoidal with the steepest slop in the middle. The EC50 (half-maximal effective
concentration) or IC50 (half-maximal inhibitory concentration) point is defined as the
inflection point of the curve. Knowledge of the dose-response relationship allows one to

10

determine the thresholds for the adverse effects and the rates of building up these effects
at increasing dose levels. The exposure conditions, related to patterns of response of host,
include routes of exposure, frequency and duration of exposure, mixed exposures and
environmental circumstances. Toxic agents may damage any contacted cells or affect only
specific target organs. The effects vary depending on the dosage and route of exposure.
Toxicity can result from cellular or biochemical changes, including cell replacement (e.g.
fibrosis), damage to an enzyme system, disruption of protein synthesis, production of
reactive chemicals in cells, and DNA damage.
A large number of environmental agents and drug candidates require fast and
efficient in vitro toxicological risk assessments. Quantitative HTS (qHTS) has been
adapted as a useful tool for toxicity testing, offering the benefits of reducing cost and
restricting the number of the laboratory animals needed.33 Developing a selective and
sensitive approach for in vitro toxicity testing can effectively eliminate the false
negatives—incapability of discerning the chemicals that were little concerned from those
with the greatest likelihood of having an adverse effect.34 However, limited knowledge of
mechanisms for many types of toxicity has made it difficult to design suitable in vitro
toxicity testing assays. As a result, a set of target-specific assays were generally applied in
the toxicity assessments, but the outcomes were still not satisfying.35 Developing a
selective and sensitive approach for in vitro bioactivity screening is a critical goal in
toxicology studies. Multichannel FP-AuNPs sensors capable of generating specific patterns
at low doses may provide more insights on the modes of actions and facilitate the
elimination of the false negatives in the toxicity assessment.

11

1.2

Results and Discussions

1.2.1

Fabrication of a triple-channel fluorescent protein-gold nanoparticle sensor

Figure 1.8 (a) Schematic of the FP-AuNP complex formation and structures of the
cationic AuNPs (NP1-NP5). (b) The scheme of triple-channel FP-AuNP complexes and
fluorescence titration curves for 100 nM FPs with four different cationic AuNPs (NP1NP4). The changes of fluorescence intensity were measured following the addition of
AuNPs at 250C. The solid lines represent the best curve fitting using Equation 1.1.
12

Table 1.1 Binding constant (𝐾𝑏 ) and binding stoichiometry (𝑛) between FP and AuNPs
(NP1-NP4) as determined from the fluorescence titrations.

The triple-channel fluorescent protein-gold nanoparticle sensor is formed by
cationic headgroup terminated AuNP mixed with three FPs, EBFP2 (pI 6.3, x/m 383/448
nm), EGFP (pI 6.0, x/m 488/507 nm), and tdTomato (pI 6.4, x/m 550/585 nm). To
investigate the appropriate headgroup of AuNPs for multichannel biosensing, several
previously used AuNPs were titrated with the equimolar FP mixture. The fluorescent
titration curves were fitted by the following binding model36:
𝛼

1

2

𝐾𝑏

𝐼 = 𝐼0 + [([𝐹𝑃]0 + 𝑛[𝐴𝑢𝑁𝑃]𝑡𝑜𝑡 +

) − {([𝐹𝑃]0 + 𝑛[𝐴𝑢𝑁𝑃]𝑡𝑜𝑡 +

1
𝐾𝑏

2

1
2

) − 4𝑛[𝐹𝑃]0 [𝐴𝑢𝑁𝑃]𝑡𝑜𝑡 } ]

(1.1)

In this equation, 𝐼0 is the initial fluorescence intensity, 𝐼 is the fluorescence intensity after
addition of the quencher (AuNP), [𝐹𝑃]0 represents the initial concentration of the
fluorescent signal producer (FP), [𝐴𝑢𝑁𝑃]𝑡𝑜𝑡 represents the total concentration of AuNPs,
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𝐾𝑏 is the binding constant (or the Stern-Volmer constant), and 𝑛 denotes the number of
binding sites around the AuNPs. The condition of applying this equation is 𝐾𝑏 [𝐹𝑃]0 ≫ 1.
NP1 and NP2 showed high binding affinities and different responses to three fluorescent
proteins. (Figure1.8 and Table 1.1)
Furthermore, to verify the classification capability of multichannel sensors, FPNP1 and FP-NP2 complexes were individually applied to identify 2.5 nM proteins
(fibrinogen, IgG, -antitrypsin, holo-transferrin) in a 200 fold diluted fetal bovine serum
(FBS) solution. By LDA, FP-NP1 showed 75% accuracy in the jackknifed classification
matrix. However, using the same procedure, NP2 showed only 46% accuracy. The most
significant canonical factors that represent linear combinations of the response matrices
obtained from the fluorescence-response patterns (three fluorescent signals  four proteins
 six replicates) were plotted in two dimensions (Figure 1.9). Therefore, the triple channel
FP-NP1 sensor is more promising for chemical nose sensing and applied for the following
sensing process.

Figure 1.9 Canonical score plots for the fluorescence patterns as obtained from LDA
against four protein analytes spiked in FBS at fixed concentration (2.5 nM) with 95%
confidence ellipses.
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1.2.2

Cytotoxicity testing of drugs by viability assays

Figure 1.10 Dose-response curves of DOX and TAM obtained by alamar blue assay,
using 7,500 cells per well after 24 hours of drug treatments.

Before evaluating the cell changes at various doses by triple channel FP-NP1
sensors, the cytotoxicity of the chemicals was first tested by a conventional method, alamar
blue assay. Two chemicals were selected: Doxorubicin (DOX), a topoisomerase II inhibitor
targeting DNA replication process37, and Tamoxifen (TAM), a selective estrogen receptor
modulator blocking cancer cell growth38. Both of these two chemicals induce the apoptotic
mode of the cell death. For the purpose of toxicity studies, human hepatocellular carcinoma
15

cells (HepG2) and human newborn foreskin fibroblast cells were selected. The threshold
dose, IC10, IC30, and IC50 values were carried out after 24 hours exposure to these chemicals
(Figure 1.10 and Table 1.2). To obtain these values, the dose-response curves were fitted
to the Hill equation.39
Table 1.2 Threshold doses and IC values obtained from dose-response curves fitted to
the Hill equation.

1.2.3

Unbiased sensing at varied doses using multichannel sensors
IC50s have been used to categorize the mechanism of actions of chemotherapeutic

drugs with BT549 cell line.31 For these two drugs, fluorescent signal patterns generated by
triple channel FP-NP1 sensors could further illustrate the cellular responses related to the
relative mechanisms of actions at low drug doses (Figure 1.11). It is noticeable that at the
threshold dose, HepG2 showed higher fluorescent intensities when exposed to TAM than
to the control (1% DMSO), which means that cells had undergone proliferation rather than
death. This effect is called hormesis, and will be further discussed in the Chapter 2. This
interesting finding implies that in order to determine in vitro NOAEL, additional bioassays
should be applied to evaluate the response around the threshold dose and multichannel FPNP1 sensors could be a powerful tool.
By LDA, the fluorescence patterns at thresholds, IC10s, and IC30s can be easily
characterized to classify the activities of the cells at these doses. For fibroblast, the clusters
16

at respective doses of these two drugs (thresholds or different ICs), always partially overlap
with each other, which implies the similarity on the cell responses. In contrast, for HepG2,
the clusters at either thresholds or different ICs, are well separated for these two drugs,
which means that there may be two distinct mechanisms of actions. For the same cell line
and drug, the separation of clusters among different doses also reveals the effects of doses
on the cell responses.

Figure 1.11 Differentiation of cell responses to DOX and TAM at three low doses
(threshold doses, IC10s, and IC30s). (a) Changes in fluorescence intensities (mean of six
replicates) for two cell lines treated with DOX or TAM individually (control in 1%
DMSO). (b) Canonical plots of discriminant scores with 95% confidence ellipses for all
data points.
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1.3

Conclusions
An unbiased triple channel sensor comprised of triple channel FPs and NP1 was

presented to identify the cell responses exposed at low doses. The results demonstrate the
power of triple channel FP-NP1 sensor in evaluating the cell responses around threshold
doses and classifying the cell specific modes of actions in in vitro toxicity testing. As a
candidate of cell-based HTS, this method can accelerate the testing procedure and eliminate
the possibility of false negatives in toxicity assessments.

1.4

Experimental Methods

1.4.1

Expression and purification of fluorescent proteins
EBFP2, EGFP and tdTomato genes were reconstructed into pQE80 plasmid. E. coli

BL21 (DE3) strain was transformed with the respective plasmids. The culture grew in LB
media at 370C until OD reaches 0.6. After the overnight induction of IPTG at 250C, cells
were harvested and the pellets were lysed using lysozyme. The fluorescent proteins in the
lysed supernatant were purified using HisPur Cobalt columns. The purified proteins were
dialyzed in 5 mM sodium phosphate buffer (pH 7.4). The purity and concentration were
determined by SDS-PAGE and absorbance spectroscopy.

1.4.2

Fluorescence titrations and protein sensing
In fluorescence titration experiments, the NPs were titrated into 100 nM equimolar

FPs in sodium phosphate buffer (pH 7.4). The changes of fluorescence intensities at 450
nm, 510 nm and 585 nm, were measured on a Molecular Devices SpectraMax M3
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microplate reader at 250C with excitation wavelengths of 380 nm, 475 nm and 550 nm,
respectively.
For serum protein sensing, 5 uL proteins spiked in diluted FBS were added into 200
uL FP-AuNP solutions on a 96-well plate. After incubation of 30 minutes, the fluorescence
intensities were measured using the same method in the previous titration experiment. The
data matrix was processed by LDA using SYSTAT software.

1.4.3

Threshold doses, IC10s, IC30s determination
Fibroblastic and HepG2 cells were seeded at 7500 cells / well in 96-well plates 24

hours prior to the drug treatments. After the addition of DOX and TAM (in 1% DMSO)
for 24 hours, the cells were washed twice with PBS and treated with 10% alamar blue in
serum-containing media for 3 hours. The substrate fluorescence intensity was read at
535/590 nm (x /m). The dose-response curves were fitted to the Hill equation, yielding
threshold doses, IC10s, IC30s and IC50s.

1.4.4

Cell sensing studies using multichannel sensors
After being treated with DOX and TAM at threshold doses, IC10s, and IC30s, HepG2

and fibroblastic cells were carefully washed by PBS buffer twice and 200 uL triple channel
FP-NP1 sensors were added. After half an hour, the plates were read through the plate
reader (at 250C). The results were analyzed by LDA.
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CHAPTER 2
CELL-BASED SENSING OF ENDOCRINE DISRUPTING CHEMICALS USING
GREEN FLUORESCENT PROTEIN-GOLD NANOPARTICLE COMPLEXES
2.1

Introduction

2.1.1

Hormones and endocrine disrupting chemicals
Steroid hormones are a class of regulatory biomolecules that play a central role in

the control of a variety of physiological and behavioral activities, including metabolism,
tissue function, sensory perception, growth and development, reproduction, stress and
mood.1 Estradiol (E2 or 17-estradiol), the principle hormone, is derived from cholesterol
and synthesized by testosterone aromatization (Figure 2.1).2 The aromatase enzymes can
be found in many tissues, including brain, skin, blood vessels, and even breast cancer
tumors.3 E2 can passively diffuse through the cell plasma membrane and interact with
cytoplasmic hormone-specific estrogen receptors (ERs). After activated by E2, dimeric
ERs translocate into the nucleus and bind to estrogen response elements (EREs) on DNA
sequences to regulate the expression of specific genes. ER is a member of the nuclear
receptor (NR) superfamily of estrogen receptor-like, also including the androgen receptor
(AR), progesterone receptor (PR), mineralcorticoid receptor (MR), and glucocorticoid
receptor (GR).4 ERs include ER, ERand G-protein-coupled estrogen receptor 1
(GPER).5 ER and ERcan form homodimers or heterdimers and exhibit distinct
transcriptional properties.
Endocrine disrupting chemicals (EDCs) are compounds, either natural or synthetic,
which interfere with endocrine systems through environmental or inappropriate
developmental exposures and produce adverse health effects in both human and wildlife,
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such as the development of hormone-dependent cancers, disorders of the reproductive tract,
obesity and reduction of sperm counts.6 EDCs represent a broad class of molecules,
including environmental pollutants and industrial chemicals, such as pesticides and
thermoplastics7.
Bisphenol A (BPA) is used in the production of polycarbonate and epoxy resins,
which are widely coated on the inside of food and beverage cans. (Figure 2.1) BPA, as an
example of EDCs, has been shown to mediate ER activity in a number of in vitro and in
vivo assays.8 Known as a potential hazard to infants and young children, BPA usage was
banned in baby bottles and infant formula packaging.

Figure 2.1 Structures of selective and nonselective ER ligands. Compounds shown
include E2 (nonselective activators), TAM (selective ER modulator), xenoestrogen
BPA, and a selective ER downregulator ICI 182,780 (ICI).
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2.1.2

The cellular estrogen signaling pathways

Figure 2.2 Schematic model illustrating genomic and non-genomic estrogen signaling
pathways. E2 activates ER and ER, inducing dimerization and binding to the
promoters of target genes. Alternatively, other classes of TFs (transcription factors) can
also be modulated by activated ERs. A small population of activated ERs at the plasma
membrane (mER) interact with adaptor proteins and signaling molecules such as c-Src,
and regulate rapid (non-genomic) effects or gene transcription via PI3K/AKT
(phosphatidylinositol 3-kinase/protein kinase B) and MAPK (mitogen-activated protein
kinase) pathways. E2, or selective ER ligands (such as G-1, ICI, and TAM), can activate
intracellular GPER, which stimulates cAMP production, calcium mobilization and cSrc, which activates MMPs (matrix metalloproteinases). MMPs cleave pro-HB-EGF
(pro-heparin-binding-epidermal growth factor), releasing free HB-EGF that
transactivates EGFR (EGF receptor), which also in turn activates PI3K/AKT and MAPK
pathways. (Ref. 5)
E2 regulates human physiology via two types of cellular signaling pathways,
genomic and non-genomic pathways (Figure 2.2).2,5 ER and ER are encoded by different
genes located on different chromosomes, yet sharing high sequence homology. There are
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several common regions, mainly including the DNA binding domain (DBD), ligand
binding domain (LBD), and hinge domain. DBD allows the dimerization of ERs and binds
to ERE sequences through zinc finger structures. LBD contains the E2 binding domain and
regulates the gene transcription with co-activators. The hinge domain (D domain) plays a
role in ER dimerization and binding to chaperone heat-shock proteins (Figure 2.3).

Figure 2.3 (a) Domain organization of ER and ER. ERs consist of N-terminal domain
(NTD, in red), DNA binding domain (DBD, in green), the hinge region (D domain, in
blue), ligand binding domain (LBD, in yellow), and C-terminal end (in grey). (b)
Binding mode of ERE to dimeric ER (PDB: 1HCQ) (c) Structures of ER and
ERbound to E2 (PDB: 1A52 and 3OLS). (Ref. 9)
There are direct and indirect action modes in the genomic pathways. The direct
action mode has been described previously, in which an ERE-like sequence should be
constructed within the promoter. However, without any ERE-like sequences, a second
DNA-binding transcription factor is needed to mediate ER indirect association with DNA.
ER and ER are shown to signal in opposite ways through interaction with different co26

regulators. For example, in the presence of E2, ER enhances the binding of specificity
protein-1 (Sp-1) in GC-rich regions to increase the transcription of a number of genes, such
as the low-density lipoprotein (LDL) receptor and cyclin D1, but ER cannot form any
transcriptionally active complex at the promoter region.2 The differences in their
transcriptional activities may result in their tissue specific biological actions.
The genomic action of E2 occurs after a time-lag of at least 2 hours after stimulation,
and however, ER-E2 complexes can activate non-genomic pathways, such as the process
of kinase-dependent phosphorylation, rapidly within minutes10. There are a subpopulation
of ERs located at the plasma membrane. The confirmation changes of ER LBD domain
after the stimulus of E2, allow ER-E2 complexes to interact with adapter proteins to
activate the downstream signaling pathways. Rapid signaling through GPER occurs via
transactivation of EGFR, involving nonreceptor tyrosine kinases of the Src family, MMP
and HB-EGF. (Figure 2.2) Non-genomic signals mediate cell-specific functions, such as
proliferation effects and neural functions.

2.1.3

Low dose effects and non-monotonic dose responses
From the National Toxicology Program’s (NTP) peer review of the low-dose EDC

in 2001, low dose effects are defined as biological changes occurring in the range of
environmentally relevant exposure levels or at a dose lower than those typically used in the
U.S. Environmental Protection Agency’s (EPA) standard toxicity testing protocols.11 There
are different low dose cut-offs for the environmental exposure level and traditional
toxicology assays. As an example, the low dose cut-off of BPA was set at 100 nM (~ 0.02
mg/L) for in vitro studies and 17.2 mg/L for aquatic animals.12 A large number of studies
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have shown that at or below the low dose cut-off the endocrine disrupting activities still
exist. As potential adverse health threaten to human, low dose effects should receive more

Figure 2.4 Examples of NMDRCs. High doses (shown by dotted line) are tested to
obtain the maximum tolerated dose (MTD), the lowest observed adverse effect level
(LOAEL), and NOAEL. Safety factors are applied to derive the “safe” dose. However,
in the actual dose-response curves, U-shaped (A) and inverted U-shaped (B) NMDRCs
shown by solid lines, the adverse effects may be observed below the “safe” dose. B
represents the response of EDCs. Both endogenous and exogenous effects are present.
No dose in this range can be considered safe. (Ref. 8)
attention.
Non-monotonic dose response curves (NMDRCs) are found in EDC studies.8
Typically, the monotonic dose response curve, linear or nonlinear, refers to a greater
response in the test as the dose increases. However, the slope of the NMDRC changes the
sign at some point within the range of doses. It is usually a U-shaped or inverted U-shaped
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curve. The existence of NMDRCs means that the high dose toxicity assessments cannot
predict the safety at lower doses, perhaps leading to false negatives (Figure 2.4).
Low dose effects of EDCs should be distinguished from hormesis, a non-monotonic
or biphasic dose response, which typically refers to the low-dose beneficial and high-dose
detrimental pattern under the biological and ecological context of the response (Figure
2.5).13 One example of hormesis is that some anticancer drugs (e.g. TAM) can enhance the
tumor cell proliferation at low doses.14 The main issue of low dose effects is that it is still
under debate how to define adverse health effects at the low-dose exposure of EDCs.

Figure 2.5 A representative dose response curve indicating the quantitative features of
hormesis. (Ref. 15)

2.1.4

In vitro assays for assessing endocrine disrupting chemicals
In vivo assays assessing EDCs are not suitable for large-scale screening and limited

due to the poor sensitivity, modest responsiveness and high cost. They utilize highly
complex responses that may not directly involve ERs, and therefore cannot be selective to
EDCs. As a comparison, in vitro assays are designed based on well elucidated mechanisms
of actions of EDCs, which can be used to rapidly prioritize and identify estrogen-like
properties of chemicals.16
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The major in vitro assays for assessing the estrogenicity can be categorized into
several groups: ER competitive ligand binding assays, cell proliferation assays (E-screen
assays17 or flow cytometric assays18), enzyme activity assays, reporter gene assays, and
yeast-based assays.16 As discussed previously, EDCs can have numerous impacts on gene
expression, activities of transcription factors, and activations of signal transduction
pathways. As a consequence, multitude of responses, such as cell growth, development,
differentiation and homeostasis, may be elicited by the interplay between various
mechanisms. There are limitations and potential problems of current in vitro assays, hence
it is unrealistic to assume one assay is capable of predicting all the responses, and the
assessments should be confirmed by other in vitro or in vivo assays. For example,
endogenous promoter-regulated reporter gene assays are susceptible to the mechanisms
that are not mediated by ERs, whereas they can provide high responsiveness and
sensitivity.19 Also, ERE-regulated reporter gene assays in which the introduction of the
reporter gene only occurs through the ERE, exhibit a low responsiveness to the antagonist,
in the presence of dextran-coated charcoal-treated fetal bovine serum (DCC-FBS).20 For
E-screen assays, long incubation period, discrepancies of estrogenicity identification using
assays based on different cell lines, and interference by other NRs, may be a concern.21
Despite these drawbacks, cell proliferation assays rarely report false positives and still one
of the most sensitive in vitro assays to assess estrogenic activities.
As the requirement of testing the estrogenic activity of thousands of chemicals
currently used in the United States, including the substances found in the drinking water
and all the pesticides, an effective, responsive, and sensitive in vitro EDC screening assay
should be developed.
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2.2

Results and discussions

2.2.1

Cell viability tests by GFP-AuNP sensor and conventional methods

Figure 2.6 The cell proliferation tests of MCF7 cells were performed by GFP-AuNP
sensor, alamar blue reagent, and Hoechst 33342 stain. The dotted plots were linearly
fitted.
As discussed previously, the cell proliferation assay, at present, is one of the most
reliable assays in detecting EDCs, which implies that this sensing mechanism is effectively
representative. Before applying the GFP-AuNP sensors to detect EDCs, its responsiveness
to the cell proliferation should be investigated. Cationic benzyl headgroup gold
nanoparticle is selected to fabricate the GFP-AuNP sensor due to its high binding affinity
to GFP or even ERs potentially. Alamar blue and nuclear stain Hoechst 33342 are applied
for comparison. The alamar blue reagent can be reduced by viable cells to indicate red
fluorescence. Hoechst 33342 is a cell permeable stain, exhibiting distinct blue fluorescence
after binding into the minor groove of DNA, which can be used to quantify DNA in solution.
From 1k to 10k MCF7 cells per well on the 96-well plates, the slopes of the normalized
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fluorescent intensity change plots show that the GFP-AuNP sensor is 3.5 times more
responsive than Hoechst 33342 and 6 times than the alamar blue reagent. (Figure 2.6)
Compared with alamar blue reagent, Hoechst 33342 stain does not interfere with FP-AuNP
sensors and can be applied in the same well in the following sensing procedure.

2.2.2

Endocrine disrupting chemicals sensing using GFP-AuNP sensors
The effects of E2 and BPA on the cell proliferation of growth arrested BT549,

MCF7 and T47D were tested using the GFP-AuNP sensor and Hoechst 33342 stain after
24 hours incubation (Figure 2.7). To maintain the low steroid conditions before exposed to
EDC containing media, DCC-FBS, phenol red free DMEM/F12 media, and phenol red free
trypsin-EDTA solution were used. As a negative control, BT549 cell line, which lacks ERs,
did not indicate any obvious cell proliferative responses to E2 or BPA with the GFP-AuNP
sensor or Hoechst 33342 stain. Notably, MCF7 and T47D, both containing ERs,
demonstrated clear dose responses to E2 and BPA by the GFP-AuNP sensor. In the
presence of 10 nM ICI 182,780 (ICI), a strong antiestrogen, the proliferative effects of E2
and BPA were suppressed, which could also be shown by the GFP-AuNP sensor. For only
24 hours incubation of E2 and BPA, Hoechst 33342 was not responsive enough to clearly
identify their estrogenic activities. The dose response curves were fitted by the Hill
equation22 to obtain EC50s and threshold doses (>15% of the maximum response, which is
roughly equal to the SD value) (Table 2.1). For both MCF7 and T47D cell lines, the EC50
values of E2 and BPA are less than 10-3-fold of the ones measured by E-screen assays.17,23
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Figure 2.7 Dose-response relationships of MCF7 (a), T47D (b) and BT549 (c) cell lines
exposed to E2, BPA and ICI using GFP-AuNP sensor and Hoechst 33342 stain. Each
value is the mean of three replicates.
Indicated by the GFP-AuNP sensor, the maximum responses of E2 and BPA on
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MCF7 cell line remained constant at higher concentrations. However, for T47D cell line,
responses slightly decreased when the concentrations of E2 or BPA increased, which
indicates that NMDRCs may exist. Interestingly, with different lengths of E2 incubation
time on MCF7 cell line, shapes of the dose response curves also varied. For 6 hour
incubation, the cell proliferative effect appeared and the NMDRC was also demonstrated.
24 hour incubation produced the higher responses than 12 hour incubation at high doses
(Figure 2.8). GFP-AuNP sensors are able to detect the cellular changes along the genomic
estrogen signaling pathway.

Table 2.1 The cell proliferation of MCF7 and T47D induced by E2 and BPA, were
measured by GFP-AuNP sensor.

Figure 2.8 Dose-response relationships of MCF7 cells at different exposure time of E2
were tested by GFP-AuNP sensor.
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2.2.3

The mechanism of cell-based GFP-AuNP sensing strategy
Array-based GFP-AuNP methods can successfully identify and differentiate

several types of mammalian cancer cells.24 The essentials are the high sensitivity of GFPAuNP sensors and the differences of glycan signatures on the cell surfaces effectively
recognized by aromatic headgroup containing AuNPs. For the similar mechanism of
actions of EDCs on the same cell line, changes of glycan signatures on the cell surface are
subtle at different doses, and also, the enhancement of the DNA synthesis is not obvious
by Hoechst 33342 stain (Figure 2.7). It is highly possible that the increased protein
expression level is essential to the fluorescent change by GFP-AuNP sensors.

Figure 2.9 Images of MCF7 cells stained by YO-PRO-1 (green fluorescence) and PI
(red fluorescence) under different conditions: PBS buffer (a), 5 mM PB (pH 7.4) (b),
and BFP-AuNP sensor in 5 mM PB (pH 7.4) (c). Scale bar: 200 m.
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To investigate the sensing mechanism by GFP-AuNP sensors, fluorescent images
were taken at different conditions (Figure 2.9). With nucleic acid stains YO-PRO-1 and
propidium iodide (PI), the cell viabilities of MCF7 cells under different treatments were
indicated. YO-PRO-1 stain is able to pass through the plasma membranes of apoptotic cells
and labels them with green fluorescence. Necrotic cells are stained in red fluorescence by
PI. After washed in PBS buffer, very few cells (~ 5%) showed apoptotic and necrotic deaths.
In contrast, when cells were exposed in 5 mM PB (pH 7.4), most of them (~ 95%) were in
the stage of necrotic death, as indicated by the overlapped image. A similar phenomenon
was also observed in the presence of BFP-AuNP sensors. When cells die due to necrosis,
it results in the loss of cell membrane integrity and uncontrollable release of intracellular
contents. It means that in the process of testing EDCs, GFP-AuNP sensors are capable of
interacting with both cell membrane debris and intracellular network.
Furthermore, the cell stages at different doses were analyzed by flow cytometry.
Measurements were performed with E2 or E2 + ICI treated BT549, MCF7 and T47D cells
after 24 hour exposure. Before analysis by the flow cytometer, cells were treated with 70%
ethanol at -200C and stained with PI. DNA contents and cell cycle distributions were
analyzed using the Dean-Jett-Fox algorithm in FlowJo software (Figure 2.10). In all cases,
the DNA content frequency histograms displayed low RMS (root mean square) scores and
narrow G1 peaks with low coefficient of variance (CV). The E2 dose response curves using
GFP-AuNP sensors were consistent to the changes in the cell cycle distribution (Figure
2.11a). For MCF7 cell line, the percentage of cells in S-phase increased with the
concentrations of E2. In contrast, for T47D cell line, the increasing percentage of cells in
G0/G1-phase and G2/M-phase represents the growth of the cell number and protein
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synthesis demonstrating strong responses by GFP-AuNP sensors. BT549 cell line did not
display any significant changes in cell cycle, and the variations were less than 3% in total
population. Interestingly, changes in G2/M-phase could be correlated to the cell lysate
studies using GFP-AuNP sensors as well (Figure 2.11b).

Figure 2.10 Representative examples of DNA histograms obtained from BD LSR II.
Green, yellow and cyan areas of histograms represent G1, S and G2/M phases.
Overall, our cell-based GFP-AuNP sensing method utilizes the necrotic cell death
to detect stages of DNA synthesis, the cell number, changes on the cell plasma membrane,
and protein expression levels. The responses of sensors indicate the quantitation of analytes.

2.3

Conclusions
This study demonstrates that the cell-based GFP-AuNP sensing method is a

promising HTS tool to rapidly detect EDCs at ultra-low doses. It offers an easy and
sensitive measurement of changes in stages of specific cells at a range of exposure
concentrations and time. Forcing cell death in necrosis helps GFP-AuNP sensors indicate
the intracellular genomic signaling pathway. The abilities to detect low dose effects and
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display NMDRCs are additional values of our sensing method as compared to other in vitro
EDC screening assays.

Figure 2.11 (a) Comparison of cell cycle analysis on alcohol fixed cells after exposed
to E2 and E2+ICI for 24 hours. 0.1% EtOH was used as control. (b) The dose-response
relationships of cell lysates using GFP-AuNP sensors. The lysates were collected after
the cells exposed to E2 and E2 + ICI for 24 hours.
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2.4

Experimental Methods

2.4.1

Comparison of measuring cell proliferation by GFP-AuNP complexes, alamar
blue reagent and Hoechst 33342 stain
A range of MCF7 cells (2,000-9,000 cells per well) were seeded in 96-well black-

wall, clear bottom microplates with phenol red free DMEM/F-12 containing 2.5% DCCFBS for overnight. The cells were washed by PBS twice before applying GFP-AuNP
complexes, alamar blue reagent (x/m: 535 nm/590 nm), or Hoechst 33342 stain (x/m:
355 nm/460 nm). 100 nM cationic benzyl headgroup AuNP and 150 nM EGFP were mixed
in 5 mM PB (pH 7.4) to form GFP-AuNP sensors. 10% alamar blue in serum-containing
media was added for 3 hour 370C incubation before measurements. Cells were incubated
with Hoechst 33342 stain for 15 minutes and washed twice by PBS. The fluorescent
intensities were monitored using Molecular Devices SpectraMax M3 microplate reader (at
250C).

2.4.2

Cell-based sensing E2 and BPA using GFP-AuNP complexes and Hoechst
33342 stain
MCF7, T47D, BT549 cell lines were initially cultured in DMEM containing 10%

dialyzed FBS, 1% antibiotics (100 U/ml penicillin and 100 g/ml streptomycin). Cells were
grown in a humidified 370C incubator under a 5% CO2 atmosphere. To maintain the
consistent results, cells were split with a maximum of 20 passages. In all experiments,
assays were performed under low steroid conditions with DCC-FBS. To minimize the
estrogenic activity of serum and synchronize the cells in G0/G1 phase of the cell cycle,
phenol red-free DMEM/F-12 containing 5% DCC-FBS and 1% antibiotics was used to
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treat the cells for 72 hours. Then, 125 uL 5000 cells per well were seeded in 96-well blackwall, clear-bottom microplates with phenol red free DMEM/F-12 containing 2.5% DCCFBS and 1% antibiotics for another 24 hours before adding E2 or BPA. E2, BPA and ICI
was dissolved in pure ethanol, protected from the light and stored at -200C. Final ethanol
concentration in media did not exceed 0.2%. The plates were carefully washed by PBS
buffer twice before applying GFP-AuNP sensors or Hoechst 33342 stain. The fluorescent
intensities were measured on the microplate reader. The dose responses curves were fitted
using the Hill equation.

2.4.3

Fluorescent imaging using YO-PRO-1 and PI stain
5,000 MCF7 cells per well were placed in the 96-well clear bottom plates. YO-

PRO-1 and PI stain were mixed in the respective media. The media was added to the cells
after cells were washed twice in PBS buffer. After 30 minute incubation, the images were
taken under the fluorescence microscope with blue and green excitation fluorescence filters.
Instead of GFP-AuNP complexes, EBFP2 were applied to mix with the same AuNPs to
avoid the green fluorescence interference with YO-PRO-1.

2.4.4

Flow cytometric analysis of MCF7, T47D and BT549 cells at different E2 doses
60,000 MCF7, T47D and BT549 cells were seeded per well in 24-well plates and

allowed to grow overnight. Cells were exposed to the same amount of E2 as previous
studies for 24 hours. After trypsinized and centrifuged, cells were added 70% ethanol and
incubated at -200C for 2 hours minimum. Then ethanol was removed and PI/RNase stain
was added. After 15 minute incubation, data of 10,000 single cell events were collected
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with BD LSR II flow cytometer using a 488 nm excitation laser and a 575/26 nm bandpass
filter. With cell doublets and aggregates gated out, the DNA content histograms were
analyzed using FlowJo software.

2.4.5

Cell lysate studies using GFP-AuNP complexes
Cells were seeded in 24-well plates as the previous study. After 24 hour E2

exposure, cells were washed by PBS twice and treated by lysis buffer [0.15 mmol/L NaCl,
5 mmol/L EDTA, 1% Triton-X 100, 10 mmol/L Tris-HCl (pH 7.4), plus half of a tablet of
complete protease inhibitor cocktail in 50 mL buffer] for 10 minutes at 40C. The lysates
were spun down at 40C for 15 min at 14000 rpm and ~200 ng of the supernatants were
analyzed by GFP-AuNP sensors.

2.5
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